Taking imatinib platelet reduction is an adverse drug reaction. Imatinib for the treatment of chronic granulocytic leukemia has an important role, the drug for molecular targeted therapy, has strong efficacy, a few patients with the drug will appear bone marrow suppression, causing red blood cells, platelet reduction, triggering anemia and bleeding symptoms. When platelet reduction occurs, skin purpura, nosebleeds or excessive menstruation may occur in women. Patients with these symptoms should consult their physician for treatment to determine if they can continue to use Imatinib. If a patient develops acute severe thrombocytopenia that triggers internal bleeding, platelet transfusions may be used to treat the bleeding symptoms. The drug should be used under medical supervision, and if there is any discomfort, seek medical attention.